Duration of type 2 diabetes and very low density lipoprotein levels are associated with cognitive dysfunction in metabolic syndrome

Cardiovascular Psychiatry and Neurology

Volumn 2014, Issue , 2014, Pages

  Yogi Morren, Divya ^a   Galioto, Rachel ^b   Strandjord, Sarah Elizabeth ^a   Kennedy, L ^a   Manroa, Pooja ^a   Kirwan, John P ^a   Kashyap, Sangeeta ^a   Gunstad, John ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b KENT STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATTENTION; BODY MASS; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE DURATION; EXECUTIVE FUNCTION; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MALE; MEMORY; METABOLIC SYNDROME X; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PROSPECTIVE STUDY; RISK FACTOR; WORKING MEMORY;

EID: 84904108993     PISSN: 20900163     EISSN: 20900171     Source Type: Journal    
DOI: 10.1155/2014/656341     Document Type: Article

References (40)

1. Nathan D. M., Long-term complications of diabetes mellitus. The New England Journal of Medicine 1993 328 23 1676 1685 10.1056/NEJM199306103282306 2-s2.0-0027253061 (Pubitemid 23157351)
2. Strachan M. W. J., Reynolds R. M., Marioni R. E., Price J. F., Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nature Reviews Endocrinology 2011 7 2 108 114 10.1038/nrendo.2010.228 2-s2.0-79251635233
3. Biessels G. J., Staekenborg S., Brunner E., Brayne C., Scheltens P., Risk of dementia in diabetes mellitus: a systematic review. The Lancet Neurology 2006 5 1 64 74 10.1016/S1474-4422(05)70284-2 2-s2.0-29044449855 (Pubitemid 41790697)
4. Cukierman T., Gerstein H. C., Williamson J. D., Cognitive decline and dementia in diabetes-systematic overview of prospective observational studies. Diabetologia 2005 48 12 2460 2469 10.1007/s00125-005-0023-4 2-s2.0-28444491100 (Pubitemid 41738208)
5. Strachan M. W. J., Deary I. J., Ewing F. M. E., Frier B. M., Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 1997 20 3 438 445 10.2337/diacare.20.3.438 2-s2.0-0031025854 (Pubitemid 27098239)
6. Kumari M., Marmot M., Diabetes and cognitive function in a middle-aged cohort: findings from the Whitehall II study. Neurology 2005 65 10 1597 1603 10.1212/01.wnl.0000184521.80820.e4 2-s2.0-28044462198 (Pubitemid 41689475)
7. van den Berg E., Reijmer Y. D., DeBresser J., Kessels R. P., Kappelle L. J., Biessels G.J., A 4-year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus. Diabetologia 2010 53 1 58 65 MR2896114
8. Vanhanen M., Koivisto K., Karjalainen L., Helkala E., Laakso M., Soininen H., Riekkinen P. Sr., Risk for non-insulin-dependent diabetes in the normoglycaemic elderly is associated with impaired cognitive function. NeuroReport 1997 8 6 1527 1530 10.1097/00001756-199704140-00041 2-s2.0-0030904246 (Pubitemid 27242569)
9. Gold S. M., Dziobek I., Sweat V., Tirsi A., Rogers K., Bruehl H., Tsui W., Richardson S., Javier E., Convit A., Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia 2007 50 4 711 719 10.1007/s00125-007-0602-7 2-s2.0-33847652525 (Pubitemid 46355836)
10. Spauwen P. J. J., Köhler S., Verhey F. R. J., Stehouwer C. D. A., van Boxtel M. P. J., Effects of type 2 diabetes on 12-year cognitive change: results from the Maastricht aging study. Diabetes Care 2013 36 6 1554 1561 10.2337/dc12-0746 2-s2.0-84878222639
11. Tran D., Baxter J., Hamman R. F., Grigsby J., Impairment of executive cognitive control in type 2 diabetes, and its effects on health-related behavior and use of health services. Journal of Behavioral Medicine 2013 37 3 414 422 10.1007/s10865-013-9499-4 2-s2.0-84873970954
12. Cukierman-Yaffe T., Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care 2009 32 8, article e103 10.2337/dc09-0821 2-s2.0-68149131622
13. Sommerfield A. J., Deary I. J., Frier B. M., Acute hyperglycemia alters mood state and impairs cognitive performance in people with type 2 diabetes. Diabetes Care 2004 27 10 2335 2340 10.2337/diacare.27.10.2335 2-s2.0-4644233538 (Pubitemid 39281382)
14. Launer L. J., Miller M. E., Williamson J. D., Lazar R. M., Gerstein H. C., Murray A. M., Sullivan M., Horowitz K. R., Ding J., Marcovina S., Lovato L. C., Lovato J., Margolis K. L., O'Connor P., Lipkin E. W., Hirsch J., Coker L., Maldjian J., Sunshine J. L., Truwit C., Davatzikos C., Bryan R. N., Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. The Lancet Neurology 2011 10 11 969 977 10.1016/S1474-4422(11)70188-0 2-s2.0-80054748660
15. Lorenzo C., Okoloise M., Williams K., Stern M. P., Haffner S. M., The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 2003 26 11 3153 3159 10.2337/diacare.26.11.3153 2-s2.0-0242300702 (Pubitemid 37339513)
16. Cavalieri M., Ropele S., Petrovic K., Pluta-Fuerst A., Homayoon N., Enzinger C., Grazer A., Katschnig P., Schwingenschuh P., Berghold A., Schmidt R., Metabolic syndrome, brain magnetic resonance imaging, and cognition. Diabetes Care 2010 33 12 2489 2495 10.2337/dc10-0851 2-s2.0-79951705805
17. Akbaraly T. N., Kivimaki M., Shipley M. J., Tabak A. G., Jokela M., Virtanen M., Marmot M. G., Ferrie J. E., Singh-Manoux A., Metabolic syndrome over 10 years and cognitive functioning in late midlife: the Whitehall II study. Diabetes Care 2010 33 1 84 89 10.2337/dc09-1218 2-s2.0-74249093377
18. Obisesan T. O., Hypertension and Cognitive Function. Clinics in Geriatric Medicine 2009 25 2 259 288 10.1016/j.cger.2009.03.002 2-s2.0-67449099097
19. Whitmer R. A., Gustafson D. R., Barrett-Connor E., Haan M. N., Gunderson E. P., Yaffe K., Central obesity and increased risk of dementia more than three decades later. Neurology 2008 71 14 1057 1064 10.1212/01.wnl.0000306313.89165.ef 2-s2.0-47949111598
20. Kang B. S., Yoon J. S., Sheet forming apparatus with flexible rollers. PCT Patent pending, 2013
21. Suzuki R., Ferris H. A., Chee M. J., Maratos-Flier E., Kahn C. R., Reduction of the cholesterol sensor SCAP in the brains of mice causes impaired synaptic transmission and altered cognitive function. PLoS Biology 2013 11 4 e1001532 10.1371/journal.pbio.1001532 2-s2.0-84876967280
22. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults, Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Journal of the American Medical Association 2001 285 19 2486 2497 10.1001/jama.285.19.2486 2-s2.0-0035897696
23. Silverstein S. M., Berten S., Olson P., Paul R., Williams L. M., Cooper N., Gordon E., Development and validation of a World-Wide-Web-based neurocognitive assessment battery: WebNeuro. Behavior Research Methods 2007 39 4 940 949 10.3758/BF03192989 2-s2.0-37349026630
24. Baddeley A., Emslie H., Nimmo-Smith I., The spot-the-word test: a robust estimate of verbal intelligence based on lexical decision. British Journal of Clinical Psychology 1993 32 1 55 65 10.1111/j.2044-8260.1993.tb01027.x 2-s2.0-0027407605 (Pubitemid 23087722)
25. Reitan R. M., Validity of the trail making test as an indicator of organic brain damage. Perceptual and Motor Skills 1958 8 3 271 276 10.2466/pms.1958.8.3.271 2-s2.0-0015135710
26. Walsh K. W., Understanding Brain Damage: A Primer of Neuropsychological Evaluation 1985 Churchill Livingstone
27. McEvoy L. K., Laughlin G. A., Barrett-Connor E., Bergstrom J., Kritz-Silverstein D., Der-Martirosian C., von Mühlen D., Metabolic syndrome and 16-year cognitive decline in community dwelling older adults. Annals of Epidemiology 2012 22 5 310 317 10.1016/j.annepidem.2011.12.003 2-s2.0-84860233249
28. O'Donnell M., Teo K., Gao P., Anderson C., Sleight P., Dans A., Marzona I., Bosch J., Probstfield J., Yusuf S., Cognitive impairment and risk of cardiovascular events and mortality. European Heart Journal 2012 33 14 1777 1786 10.1093/eurheartj/ehs053 2-s2.0-84867168974
29. Basile G., Crucitti A., Cucinotta M. D., Figliomeni P., Lacquaniti A., Catalano A., Morabito N., Buemi M., Lasco A., Impact of diabetes on cognitive impairment and disability in elderly hospitalized patients with heart failure. Geriatrics & Gerontology International 2013 13 4 1035 1042 10.1111/ggi.12051 2-s2.0-84875041813
30. Alosco M. L., Spitznagel M. B., van Dulmen M., Raz N., Cohen R., Sweet L. H., Colbert L. H., Josephson R., Hughes J., Rosneck J., Gunstad J., Cognitive function and treatment adherence in older adults with heart failure. Psychosomatic Medicine 2012 74 9 965 973 10.1097/PSY.0b013e318272ef2a 2-s2.0-84870248837
31. Beth Spitznagel M., Galioto R., Limbach K., Gunstad J., Heinberg L., Cognitive function is linked to adherence to bariatric postoperative guidelines. Surgery for Obesity and Related Diseases 2013 9 4 580 585 10.1016/j.soard.2013. 04.007 2-s2.0-84881186111
32. Stitt A. W., Advanced glycation: An important pathological event in diabetic and age related ocular disease. British Journal of Ophthalmology 2001 85 6 746 753 10.1136/bjo.85.6.746 2-s2.0-0034985014 (Pubitemid 32554256)
33. Brownlee M., Advanced protein glycosylation in diabetes and aging. Annual Review of Medicine 1995 46 223 234 10.1146/annurev.med.46.1.223 2-s2.0-0028908348
34. Park H. S., Park J. Y., Yu R., Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF- α and IL-6. Diabetes Research and Clinical Practice 2005 69 1 29 35 10.1016/j.diabres.2004.11.007 2-s2.0-20444480549 (Pubitemid 40813409)
35. Jakobsen J., Nedergaard M., Aarslew-Jensen M., Diemer N. H., Regional brain glucose metabolism and blood flow in streptozocin-induced diabetic rats. Diabetes 1990 39 4 437 440 10.2337/diab.39.4.437 2-s2.0-0025363792 (Pubitemid 20111424)
36. Chen R., Jiang X., Zhao X., Qin Y., Gu Z., Gu P., Zhou B., Zhu Z., Xu L., Zou Y., Risk factors of mild cognitive impairment in middle aged patients with type 2 diabetes: a cross-section study. Annals of Endocrinology 2012 73 3 208 212 10.1016/j.ando.2012.04.009 2-s2.0-84863821108
37. Vikarunnessa S., Weiner M. F., Vega G. L., LDL phenotype in subjects with mild cognitive impairment and Alzheimer's disease. Journal of Alzheimer's Disease 2013 36 3 571 575 10.3233/JAD-130443 2-s2.0-84881423555
38. Chaudhary R., Likidlilid A., Peerapatdit T., Tresukosol D., Srisuma S., Ratanamaneechat S., Sriratanasathavorn C., Apolipoprotein E gene polymorphism: Effects on plasma lipids and risk of type 2 diabetes and coronary artery disease. Cardiovascular Diabetology 2012 11, article no. 36 10.1186/1475-2840- 11-36 2-s2.0-84859929415
39. Beydoun M. A., Beason-Held L. L., Kitner-Triolo M. H., Beydoun H. A., Ferrucci L., Resnick S. M., Zonderman A. B., Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. Journal of Epidemiology and Community Health 2011 65 11 949 957 10.1136/jech.2009.100826 2-s2.0-80955135450
40. Cramer C., Haan M. N., Galea S., Langa K. M., Kalbfleisch J. D., Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008 71 5 344 350 10.1212/01.wnl.0000319647.15752.7b 2-s2.0-67649252917